ProPhase Labs, Inc. Net Cash Provided by (Used in) Operating Activities, Continuing Operations
ProPhase Labs, Inc. (PRPH) reported Net Cash Provided by (Used in) Operating Activities, Continuing Operations of -$826.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations · last filed 2026-08-19
- ProPhase Labs, Inc. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2026-06-30 was -$78.00K.
- ProPhase Labs, Inc. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2026-03-31 was -$748.00K.
- ProPhase Labs, Inc. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2025-12-31 was -$1.23M.
- ProPhase Labs, Inc. net cash provided by (used in) operating activities, continuing operations for the quarter ending 2025-09-30 was -$3.49M.
- ProPhase Labs, Inc. net cash provided by (used in) operating activities, continuing operations for fiscal 2025 was -$8.94M.
- ProPhase Labs, Inc. net cash provided by (used in) operating activities, continuing operations for fiscal 2024 was -$11.80M.
- ProPhase Labs, Inc. net cash provided by (used in) operating activities, continuing operations for fiscal 2023 was -$12.19M.
- ProPhase Labs, Inc. net cash provided by (used in) operating activities, continuing operations for fiscal 2014 was -$3.22M, a 382.85% decline from fiscal 2013.
| Period end | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Operating Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$78.00K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-19 | -$826.00K 10-Q · filed 2026-08-19 | -$2.06M derived: sum of 3 quarters · filed 2026-08-19 | -$5.54M derived: sum of 4 quarters · filed 2026-08-19 |
| 2026-03-31 | -$748.00K 10-Q/A · filed 2026-07-09 | -$1.98M derived: sum of 2 quarters · filed 2026-07-09 | -$5.46M derived: sum of 3 quarters · filed 2026-07-09 | -$5.71M derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-12-31 | -$1.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | -$4.72M derived: sum of 2 quarters · filed 2026-06-01 | -$4.96M derived: sum of 3 quarters · filed 2026-08-19 | -$8.94M 10-K · filed 2026-06-01 |
| 2025-09-30 | -$3.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19 | -$3.73M derived: sum of 2 quarters · filed 2026-08-19 | -$7.71M 10-Q · filed 2025-11-19 | -$10.93M derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-06-30 | -$247.00K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-19 | -$4.22M 10-Q · filed 2026-08-19 | -$7.44M derived: sum of 3 quarters · filed 2026-08-19 | -$10.28M derived: sum of 4 quarters · filed 2026-08-19 |
| 2025-03-31 | -$3.98M 10-Q/A · filed 2026-07-09 | -$7.19M derived: sum of 2 quarters · filed 2026-07-09 | -$10.04M derived: sum of 3 quarters · filed 2026-07-09 | -$12.90M derived: sum of 4 quarters · filed 2026-07-09 |
| 2024-12-31 | -$3.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-01 | -$6.06M derived: sum of 2 quarters · filed 2026-06-01 | -$8.92M derived: sum of 3 quarters · filed 2026-06-01 | -$11.80M 10-K · filed 2026-06-01 |
| 2024-09-30 | -$2.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-19 | -$5.71M derived: sum of 2 quarters · filed 2025-11-19 | -$8.59M 10-Q · filed 2025-11-19 | |
| 2024-06-30 | -$2.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$5.75M 10-Q · filed 2025-08-13 | ||
| 2024-03-31 | -$2.88M 10-Q · filed 2025-05-20 | |||
| 2023-12-31 | -$12.19M 10-K · filed 2025-04-01 | |||
| 2015-03-31 | $2.13M 10-Q · filed 2015-05-13 | $394.00K derived: sum of 2 quarters · filed 2015-05-13 | -$2.05M derived: sum of 3 quarters · filed 2015-05-13 | -$4.04M derived: sum of 4 quarters · filed 2015-05-13 |
| 2014-12-31 | -$1.74M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-27 | -$4.18M derived: sum of 2 quarters · filed 2015-03-27 | -$6.17M derived: sum of 3 quarters · filed 2015-03-27 | -$3.22M 10-K · filed 2015-03-27 |
| 2014-09-30 | -$2.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-13 | -$4.43M derived: sum of 2 quarters · filed 2014-11-13 | -$1.48M 10-Q · filed 2014-11-13 | -$622.00K derived: sum of 4 quarters · filed 2015-05-13 |
| 2014-06-30 | -$1.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-12 | $964.00K 10-Q · filed 2014-08-12 | $1.82M derived: sum of 3 quarters · filed 2015-05-13 | -$1.44M derived: sum of 4 quarters · filed 2015-05-13 |
| 2014-03-31 | $2.95M 10-Q · filed 2015-05-13 | $3.81M derived: sum of 2 quarters · filed 2015-05-13 | $547.00K derived: sum of 3 quarters · filed 2015-05-13 | $311.00K derived: sum of 4 quarters · filed 2015-05-13 |
| 2013-12-31 | $856.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-27 | -$2.40M derived: sum of 2 quarters · filed 2015-03-27 | -$2.64M derived: sum of 3 quarters · filed 2015-03-27 | $1.14M 10-K · filed 2015-03-27 |
| 2013-09-30 | -$3.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-13 | -$3.50M derived: sum of 2 quarters · filed 2014-11-13 | $281.00K 10-Q · filed 2014-11-13 | |
| 2013-06-30 | -$236.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-12 | $3.54M 10-Q · filed 2014-08-12 | ||
| 2013-03-31 | $3.78M 10-Q · filed 2014-05-12 | |||
| 2012-12-31 | -$5.73M 10-K · filed 2015-03-27 | |||
| 2011-12-31 | -$2.11M 10-K · filed 2014-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |